Published in Ann Intern Med on February 01, 1966
Profiling Neutrophil Counts in Patients on Chemotherapy | NCT02806557
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients | NCT05221593
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med (2013) 4.20
A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A (1988) 2.22
Neutrophils in innate host defense against Staphylococcus aureus infections. Semin Immunopathol (2011) 2.17
LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS One (2007) 2.01
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Cusum plotting of temperature charts for assessing antimicrobial treatment in neutropenic patients. BMJ (1989) 1.95
Detection of bacteraemia in patients with fever and neutropenia using 16S rRNA gene amplification by polymerase chain reaction. Eur J Clin Microbiol Infect Dis (1998) 1.78
Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis (2011) 1.66
Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol Microbiol (2011) 1.64
Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer (2003) 1.62
Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect Immun (2005) 1.60
Candida albicans response regulator gene SSK1 regulates a subset of genes whose functions are associated with cell wall biosynthesis and adaptation to oxidative stress. Eukaryot Cell (2003) 1.53
The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression. Cell Death Dis (2014) 1.50
G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.46
The colony-stimulating factors and cancer. Nat Rev Cancer (2010) 1.44
Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. Antimicrob Agents Chemother (1975) 1.43
Hospital discharges for fever and neutropenia in pediatric cancer patients: United States, 2009. BMC Cancer (2015) 1.41
Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer (2004) 1.38
Preventing infection in neutropenic cancer patients. West J Med (1983) 1.38
A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management. Health Phys (2012) 1.35
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med (2011) 1.32
Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. Infect Immun (2008) 1.26
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev (2012) 1.22
SKN7 of Candida albicans: mutant construction and phenotype analysis. Infect Immun (2004) 1.22
Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother (2008) 1.22
Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res (2012) 1.21
Cancer cachexia--pathophysiology and management. J Gastroenterol (2013) 1.20
Management of chemotherapy-associated febrile neutropenia. Br J Cancer (2009) 1.20
Directional decisions during neutrophil chemotaxis inside bifurcating channels. Integr Biol (Camb) (2010) 1.20
Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of impaired phagocytosis. Infect Immun (1979) 1.19
Neutrophil function in gram-negative rod bacteremia. The interaction between phagocytic cells, infecting organisms, and humoral factors. J Clin Invest (1976) 1.19
Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl Acad Sci U S A (2011) 1.18
Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis (2011) 1.16
Role of granulocytes and monocytes in experimental Staphylococcus epidermidis endocarditis. Infect Immun (1983) 1.16
Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer (2003) 1.14
Safety and effectiveness of central venous catheterization in patients with cancer: prospective observational study. J Korean Med Sci (2010) 1.12
Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. PLoS One (2010) 1.11
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob Agents Chemother (2006) 1.11
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 1.08
Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-1 alpha. Infect Immun (1989) 1.08
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer (2013) 1.05
Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer (2004) 1.01
Effect of vincristine sulfate on Pseudomonas infections in monkeys. Infect Immun (1972) 1.00
Mechanistic models for myelosuppression. Invest New Drugs (2003) 1.00
Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol (2008) 1.00
The Pathophysiology and Treatment of Candida Sepsis. Curr Infect Dis Rep (2002) 1.00
A NET Outcome. Front Immunol (2012) 1.00
Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun (1979) 0.99
G-CSF and GM-CSF in Neutropenia. J Immunol (2015) 0.98
Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica (2011) 0.98
Temporal expression of the Candida albicans genes CHK1 and CSSK1, adherence, and morphogenesis in a model of reconstituted human esophageal epithelial candidiasis. Infect Immun (2002) 0.98
Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children--a systematic review of prospective trials. Support Care Cancer (2012) 0.97
Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer (2005) 0.97
Immune status of children with and without severe infection during remission of malignant disease. Br Med J (1975) 0.97
T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis. Infect Immun (2001) 0.97
Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. Clin Adv Hematol Oncol (2013) 0.96
T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice. J Clin Invest (1986) 0.96
Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012) 0.96
In vitro susceptibility of Citrobacter species to various antimicrobial agents. Antimicrob Agents Chemother (1987) 0.96
Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer (2010) 0.95
Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol (2010) 0.94
Comparison of tobramycin, gentamicin, colistin, and carbenicillin in Pseudomonas sepsis in monkeys. Antimicrob Agents Chemother (1972) 0.94
Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis (2007) 0.93
Why pediatric patients with cancer visit the emergency department: United States, 2006-2010. Pediatr Blood Cancer (2014) 0.92
The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer (2010) 0.91
The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2009) 0.91
Deletion of the two-component histidine kinase gene (CHK1) of Candida albicans contributes to enhanced growth inhibition and killing by human neutrophils in vitro. Infect Immun (2002) 0.91
Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol (2014) 0.90
Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer (2007) 0.90
Moving CLABSI prevention beyond the intensive care unit: risk factors in pediatric oncology patients. Infect Control Hosp Epidemiol (2011) 0.90
Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis (2010) 0.90
Assessment and management of febrile neutropenia in emergency departments within a regional health authority-a benchmark analysis. Curr Oncol (2011) 0.90
Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother (1993) 0.89
Blood leucocyte count in the human fetus. Arch Dis Child (1992) 0.89
Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care (Basel) (2014) 0.88
Demonstration of a local exhaustion of complement components and of an enzymatic degradation of immunoglobulins in pleural empyema: a possible factor favouring the persistence of local bacterial infections. Clin Exp Immunol (1980) 0.88
Microbiological evaluation of protected environments during patient occupancy. Appl Microbiol (1971) 0.88
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol (2010) 0.88
Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine. Front Immunol (2014) 0.87
Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. Antimicrob Agents Chemother (1987) 0.87
Bistability and bacterial infections. PLoS One (2010) 0.86
Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia. Br J Cancer (2011) 0.86
Hospitalizations for infection in cancer patients: impact of an aging population. Support Care Cancer (2008) 0.86
Isolating patients in hospital to control infection part II--Who should be isolated, and where? Br Med J (1978) 0.86
Totally implantable subcutaneous port system versus central venous catheter placed before induction chemotherapy in patients with acute leukaemia-a randomized study. Support Care Cancer (2003) 0.85
Interferon-gamma activates the oxidative killing of Candida albicans by human granulocytes. Clin Exp Immunol (1993) 0.85
Microbial etiology of febrile neutropenia. Indian J Hematol Blood Transfus (2010) 0.85
Contaminated stethoscopes: a potential source of nosocomial infections. Yale J Biol Med (1972) 0.85
Endothelial cells are main producers of interleukin 8 through Toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients. Clin Diagn Lab Immunol (2003) 0.85
Daptomycin use in neutropenic patients with documented gram-positive infections. Support Care Cancer (2013) 0.85
How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract (2010) 0.84
Bactericidal capacity of peripheral blood leucocytes in relation to bacterial infections in acute lymphoblastic leukaemia in childhood. J Clin Pathol (1974) 0.84
Phagocytosis. Clinical disorders of recognition and ingestion. Am J Pathol (1977) 0.84
A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer (2004) 0.83
Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Support Care Cancer (2010) 0.83
Granulocyte transfusion in treatment of infected neutropenic children. Arch Dis Child (1976) 0.83
Evidence for under-diagnosis of childhood acute lymphoblastic leukaemia in poorer communities within Great Britain. Br J Cancer (2012) 0.82
Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia. Support Care Cancer (2013) 0.82
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol (2001) 3.02
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax (2005) 2.19
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15
Helicobacter pylori: the cancer link. J R Soc Med (1996) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Virus-like particles in winter vomiting disease. Lancet (1977) 2.12
Amoxicillin: in vitro and pharmacological studies. Antimicrob Agents Chemother (1972) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Infections in cancer patients. Cancer Treat Rev (1975) 2.12
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother (1981) 2.04
Ticarcillin therapy of infections. Antimicrob Agents Chemother (1973) 2.01
Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother (1983) 2.00
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother (1983) 1.93
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Klebsiella bacteremia in cancer patients. Am J Med Sci (1973) 1.87
In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1973) 1.86
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med (1979) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
The relationship between the thrombotic and infectious complications of central venous catheters. JAMA (1994) 1.85
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis (1997) 1.84
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
In vitro studies of cefamandole. Antimicrob Agents Chemother (1976) 1.81
Detection of Serratia outbreaks in hospital. Lancet (1976) 1.81
Comparative in vitro activity of cephalosporins. J Antibiot (Tokyo) (1976) 1.79
Infectious complications of indwelling vascular catheters. Clin Infect Dis (1992) 1.77
Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer (1993) 1.77
Serratia sp. infections in cancer patients. Cancer (1970) 1.73
Comparative in vitro study of temocillin (BRL 17421), a new penicillin. Antimicrob Agents Chemother (1982) 1.73
Is a picture worth a thousand medical words? A randomized trial of reporting formats for medical research data. Methods Inf Med (1991) 1.70
Epidemiological studies of Pseudomonas species in patients with leukemia. Am J Med Sci (1970) 1.70
The heart in acute leukemia. A study of 420 autopsy cases. Am J Cardiol (1968) 1.69
Influenza among hospitalized adults with leukemia. Clin Infect Dis (1997) 1.68
Non-randomized controls in cancer clinical trials. N Engl J Med (1974) 1.67
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med (1989) 1.64
Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med (2000) 1.62
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
Clinical pharmacology of sisomicin. Antimicrob Agents Chemother (1975) 1.61
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother (1995) 1.57
Infection in cancer patients. A continuing association. Am J Med (1986) 1.55
Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis (1992) 1.54
Fungal infection and fever of unknown origin in neutropenic patients. Am J Med (1986) 1.54
Mycobacteriosis in patients with malignant disease. Arch Intern Med (1976) 1.54
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol (1986) 1.54
Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. Cancer (1978) 1.53